Further Upside For Selvita S.A. (WSE:SLV) Shares Could Introduce Price Risks After 27% Bounce
Nov 27
Have your own idea? Try our Stock Screener
Polish (WIG) Clinical Research and Equipment Industry Analysis
UpdatedMar 14, 2026
DataAggregated Company Financials
Companies4
- 7D-2.6%
- 3M-7.7%
- 1Y-0.8%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 2.6%, driven by Ryvu Therapeutics declining 4.1%. As for the longer term, the industry's performance has been flat for the past year. Looking forward, earnings are forecast to grow by 79% annually.
Industry Valuation and Performance
Has the Polish Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 14 Mar 2026 | zł1.3b | zł464.6m | -zł124,641,157.00 | n/a | -10.7x | 2.9x |
| Mon, 09 Feb 2026 | zł1.4b | zł464.6m | -zł124,641,157.00 | n/a | -10.9x | 2.9x |
| Wed, 07 Jan 2026 | zł1.5b | zł464.6m | -zł124,641,157.00 | n/a | -11.8x | 3.2x |
| Fri, 05 Dec 2025 | zł1.5b | zł464.6m | -zł124,641,157.00 | n/a | -12.4x | 3.3x |
| Sun, 02 Nov 2025 | zł1.3b | zł507.6m | -zł114,663,001.00 | 1456.6x | -11.4x | 2.6x |
| Tue, 30 Sep 2025 | zł1.4b | zł507.7m | -zł114,663,001.00 | 1515.8x | -12.5x | 2.8x |
| Thu, 28 Aug 2025 | zł1.4b | zł460.9m | -zł129,094,851.00 | 37.8x | -11.1x | 3.1x |
| Sat, 26 Jul 2025 | zł1.6b | zł461.1m | -zł128,888,382.00 | 40.8x | -12.1x | 3.4x |
| Mon, 23 Jun 2025 | zł1.3b | zł457.8m | -zł130,948,382.00 | n/a | -10x | 2.9x |
| Wed, 21 May 2025 | zł1.5b | zł448.2m | -zł125,701,382.00 | n/a | -12.3x | 3.4x |
| Fri, 18 Apr 2025 | zł1.4b | zł452.3m | -zł123,092,243.00 | 49.3x | -11.7x | 3.2x |
| Sun, 16 Mar 2025 | zł1.5b | zł440.9m | -zł62,900,243.00 | 32.4x | -24.1x | 3.4x |
| Tue, 11 Feb 2025 | zł1.7b | zł427.8m | -zł64,267,017.00 | 15.5x | -26.5x | 4x |
| Thu, 09 Jan 2025 | zł2.0b | zł427.0m | -zł65,964,174.00 | 16.6x | -30.5x | 4.7x |
| Sat, 07 Dec 2024 | zł2.3b | zł427.0m | -zł66,300,174.00 | 18.1x | -35.2x | 5.5x |
| Mon, 04 Nov 2024 | zł2.3b | zł413.2m | -zł64,500,689.00 | 20.8x | -35.2x | 5.5x |
| Wed, 02 Oct 2024 | zł2.3b | zł413.2m | -zł57,384,869.00 | 22.3x | -40.5x | 5.6x |
| Fri, 30 Aug 2024 | zł2.5b | zł413.4m | -zł37,576,869.00 | 18.7x | -67x | 6.1x |
| Sun, 28 Jul 2024 | zł2.5b | zł413.5m | -zł32,092,283.00 | 18.4x | -77.1x | 6x |
| Tue, 25 Jun 2024 | zł2.5b | zł413.5m | -zł32,092,283.00 | 18.7x | -76.5x | 5.9x |
| Thu, 23 May 2024 | zł2.6b | zł428.1m | -zł27,509,283.00 | 18.3x | -95.1x | 6.1x |
| Sat, 20 Apr 2024 | zł2.6b | zł421.0m | -zł26,364,957.00 | 18.2x | -97.4x | 6.1x |
| Mon, 18 Mar 2024 | zł2.6b | zł478.9m | -zł71,866,957.00 | 46.3x | -35.8x | 5.4x |
| Wed, 14 Feb 2024 | zł2.5b | zł494.7m | -zł51,178,957.00 | 44.8x | -49.5x | 5.1x |
| Fri, 12 Jan 2024 | zł2.5b | zł495.2m | -zł50,454,191.00 | 47.3x | -49.6x | 5.1x |
| Sun, 10 Dec 2023 | zł2.5b | zł495.2m | -zł50,454,191.00 | 45.2x | -49.5x | 5x |
| Tue, 07 Nov 2023 | zł2.5b | zł512.0m | -zł37,354,934.00 | 31.1x | -67.6x | 4.9x |
| Thu, 05 Oct 2023 | zł2.8b | zł515.2m | -zł43,569,514.00 | 39.9x | -63.3x | 5.4x |
| Sat, 02 Sep 2023 | zł2.8b | zł507.8m | -zł51,598,105.00 | 42.7x | -53.9x | 5.5x |
| Mon, 31 Jul 2023 | zł2.8b | zł512.4m | -zł61,559,268.00 | 45.9x | -46.1x | 5.5x |
| Wed, 28 Jun 2023 | zł2.8b | zł512.4m | -zł61,559,268.00 | 43.6x | -45x | 5.4x |
| Fri, 26 May 2023 | zł2.9b | zł507.5m | -zł59,821,034.00 | 46.5x | -48.3x | 5.7x |
| Sun, 23 Apr 2023 | zł2.8b | zł505.4m | -zł64,921,034.00 | 67.2x | -43.3x | 5.6x |
| Tue, 21 Mar 2023 | zł3.1b | zł473.8m | -zł77,860,781.00 | 75.5x | -40x | 6.6x |
Price to Earnings Ratio
-40x
Current Industry PE
- Investors are pessimistic on the Polish Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 4.6x is higher than the industry's current PS ratio of 2.9x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does Polish Clinical Research and Equipment compare with similar industries?
| PL Market | 0.054% | |
| Healthcare | -2.08% | |
| Life Sciences | -2.60% | |
| Clinical Research and Equipment | -2.60% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NNG NanoGroup | zł2.53 | 0.2% +zł164.1k | -20.7% | PB7.7x |